|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2855-2863.
Prepublished online as a Blood First Edition Paper on June 25, 2007; DOI 10.1182/blood-2007-04-082602.
 Previous Article | Table of Contents | Next Article 
GENE THERAPY
Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens
Lucienne M. Ide1,2,
Bagirath Gangadharan1,
Kuang-Yueh Chiang1,
Christopher B. Doering1, and
H. Trent Spencer1,2
1 Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Emory University and Children's Healthcare of Atlanta, GA;
2 Graduate Program in Molecular and System Pharmacology, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA
Insufficient expression of factor VIII (fVIII) is a major hurdle in the development of successful nucleic acid treatments for hemophilia. However, we recently showed that under myeloablative and reduced-intensity total body irradiation (TBI) conditioning, transplantation of hematopoietic stem cells (HSCs) transduced with recombinant retroviruses containing B domain–deleted porcine fVIII (BDDpfVIII) sequences provides curative fVIII levels in a hemophilia A mouse model. In the current study, we tested BDDpfVIII activity after nonmyeloablative conditioning with busulfan, cyclophosphamide, or fludarabine and immunosuppressive agents CTLA4-Ig + anti-CD40L or anti-(murine)thymocyte serum (ATS). ATS is similar in action to anti-(human)thymocyte globulin (ATG), which is used clinically with busulfan in bone marrow transplantations to increase donor cell engraftment. Mice conditioned with busulfan + ATS and that received a transplant of BDDpfVIII-transduced stem-cell antigen 1-positive cells exhibited moderate levels of donor cell chimerism (between 20% and 60%) and achieved sustained fVIII levels more than 1 U/mL. Similar results were observed in mice preimmunized with human fVIII and conditioned with 5 Gy TBI + ATS or busulfan + ATS. These data demonstrate that it is possible to achieve sufficient fVIII expression after transplantation of BDDpfVIII-transduced HSCs following low-toxicity pretransplantation conditioning with targeted immunosuppression, potentially even in the context of preexisting inhibitors.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Yadav, S. Kanjirakkuzhiyil, S. Kumar, M. Jain, A. Halder, R. Saxena, and A. Mukhopadhyay
The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A
Blood,
November 12, 2009;
114(20):
4552 - 4561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Peng, P. Ye, D. J. Rawlings, H. D. Ochs, and C. H. Miao
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy
Blood,
November 12, 2009;
114(20):
4373 - 4382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ramezani and R. G. Hawley
Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector
Blood,
July 16, 2009;
114(3):
526 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Shi, S. A. Fahs, D. A. Wilcox, E. L. Kuether, P. A. Morateck, N. Mareno, H. Weiler, and R. R. Montgomery
Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity
Blood,
October 1, 2008;
112(7):
2713 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Nienhuis
Development of gene therapy for blood disorders
Blood,
May 1, 2008;
111(9):
4431 - 4444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
